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Background: Up to a third of children with Autism Spectrum Disorder (ASD) manifest regressive autism (R-ASD).
They show normal early development followed by loss of language and social skills. Absent evidence-based
therapies, anecdotal evidence suggests improvement following use of corticosteroids. This study examined the
effects of corticosteroids for R-ASD children upon the 4 Hz frequency modulated evoked response (FMAER) arising
from language cortex of the superior temporal gyrus (STG) and upon EEG background activity, language, and
behavior. An untreated clinical convenience sample of ASD children served as control sample.
Methods: Twenty steroid-treated R-ASD (STAR) and 24 not-treated ASD patients (NSA), aged 3 - 5 years, were
retrospectively identified from a large database. All study participants had two sequential FMAER and EEG studies;
Landau-Kleffner syndrome diagnosis was excluded. All subjects’ records contained clinical receptive and expressive
language ratings based upon a priori developed metrics. The STAR group additionally was scored behaviorally
regarding symptom severity as based on the Diagnostic and Statistical Manual IV (DSM-IV) ASD criteria list. EEGs
were visually scored for abnormalities. FMAER responses were assessed quantitatively by spectral analysis. Treated
and untreated group means and standard deviations for the FMAER, EEG, language, and behavior, were compared
by paired t-test and Fisher’s exact tests.
Results: The STAR group showed a significant increase in the 4 Hz FMAER spectral response and a significant reduction
in response distortion compared to the NSA group. Star group subjects’ language ratings were significantly improved
and more STAR than NSA group subjects showed significant language improvement. Most STAR group children
showed significant behavioral improvement after treatment. STAR group language and behavior improvement was
retained one year after treatment. Groups did not differ in terms of minor EEG abnormalities. Steroid treatment
produced no lasting morbidity.
Conclusions: Steroid treatment was associated with a significantly increased FMAER response magnitude, reduction of
FMAER response distortion, and improvement in language and behavior scores. This was not observed in the
non-treated group. These pilot findings warrant a prospective randomized validation trial of steroid treatment for
R-ASD utilizing FMAER, EEG, and standardized ASD, language and behavior measures, and a longer follow-up period.
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TreatmentBackground
Autism Spectrum Disorders (ASD) or Autism refers to a
complex range of developmental disorders that are charac-
terized by impairments in language difficulties with social
interactions, and often rigid, repetitive and/or stereotypical
behaviors and interests. The incidence of autism has
increased over the last few decades, with as many as
one in 88 children identified with ASD [1].
Retrospective studies indicate at least three distinct
patterns of symptom onset in autism. In the most com-
mon form symptoms of autism are evident early in
infancy. In the second form, an initial period of typical
development is followed by an unexpected cessation or
significant slowing in the continued acquisition of com-
munication and/or social skills and the child reaches a
developmental plateau. In the third and perhaps most
intriguing form, often referred to as regressive autism,
a period of normal or near normal early development is
followed by a cessation of all further development and loss
of previously acquired communication and/or social skills,
most often of both [2]. In this third form, developmental
regression usually occurs between 15 to 30 months of age
and can occur rapidly over a very few days, or more slowly
in the course of several weeks or even months. Once de-
velopment has regressed, such children typically follow
the standard ASD developmental profile [3,4]. Ozonoff
et al. point out that although “more children may present
with a regressive course than previously thought parent
report methods do not capture this phenomenon well”
[5]. There may be confusion among early-starting slow re-
gression, a developmental plateau, and frank, abrupt re-
gression defined by rapid loss of previously achieved
cognitive, language, communication, and behavioral mile-
stones. Thus, anyone who studies patients with regressive
autism must define carefully the parameters of regression
applicable to the study.
ASD and in particular regressive autism have attracted
worldwide attention. Prominent and abrupt loss of mile-
stones typically results in referral to a child neurologist
in order to search for potentially relevant etiological factors
and hopefully, for initiation of remediation. Neurological
disorders associated with autism symptomatology include
Fragile X syndrome, tuberous sclerosis, Rett’s syndrome,
mitochondrial disorders, and a multiplicity of genetic
anomalies [6]. Regression associated with the Landau-
Kleffner syndrome (LKS, an epileptic encephalopathy)may also present in a manner similar to R-ASD [7,8]. An
overnight sleep electroencephalogram (EEG) may be re-
quired to diagnose and/or rule out LKS, given that the
finding of significant focal or generalized sleep-activated
discharges is taken as diagnostic for LKS [9]. To date the
cause of abrupt autistic regression often eludes identifica-
tion, despite the fact that onset of regression may appear
to follow a distinct event, such as trauma, illness, or
immunization. This report focuses exclusively upon re-
gressive autism of abrupt onset showing initial, obvious,
rapid regression over a time period of a few days to max-
imally a few weeks, followed by continuing regression at a
slower pace over the ensuing months until a stable low
functioning state is reached. This phenomenon will be
referred to as ‘R-ASD’ in the current paper. It is probable
that such abrupt regressions do not characterize the
full third of autistic children, who are reported to “show
regression” occurring across varying lengths of time [5].
The terminology used to describe regressive autism
continues to be in flux. Given the similarity of presenta-
tion in children with R-ASD and children with early
onset LKS the appellation ‘Landau-Kleffner Syndrome
variant’ (LKSv) was used and often retained even when a
definitive LKS diagnosis had been ruled out. In such
cases many epileptologists object to the ‘LKSv’ termin-
ology and increasingly utilize ‘regressive autism’ abbrevi-
ated as R-ASD, with focus upon the prominent autistic
behavioral profile following regression. However, few
R-ASD patients are evaluated early-on by ‘gold standard’
measures such as the ADOS and ADI [10,11]. Some
behavioral neurologists object to the ‘autism’ appellation
despite the evidence that most such children eventually
receive that diagnosis [3,4]. For this paper, the abbrevi-
ation R-ASD is used.
Referring physicians often enquire about the utility of ad-
renal corticosteroids or glucocorticoids to treat patients
with R-ASD. A literature review provides three possible jus-
tifications for this therapeutic approach. First are the vari-
ous similarities of R-ASD and LKS; many neurologists
consider corticosteroids the ultimate treatment for LKS
when anticonvulsants have failed [12,13]. The R-ASD - LKS
similarities considered include shared behavioral presenta-
tion [7,8], strong overlap of genetic, genomic and molecular
networks [14], and in some older R-ASD patients magne-
toencephalography (MEG) detected seizure discharges
localized to the bilateral superior temporal gyri (STG)
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EEG detected discharges in LKS [16]. Furthermore, in
addition to LKS, several other forms of refractory epilepsy
have been successfully treated using adrenal corticosteroids
[17-19]. Given these similarities in underlying pathophysi-
ology and genetics, and the potential of successful treat-
ment, there is reason to hypothesize that the two
syndromes may also share a positive response to corticoste-
roids. Second, it has been speculated that regressive autism
might be an inflammatory or auto-immune disorder
[20-22]. As corticosteroid administration constitutes an im-
portant treatment modality for the common auto-immune
diseases [23], it is reasonable to consider steroids as poten-
tially useful for R-ASD. A notable single case study dem-
onstrated autistic language regression concomitant with an
autoimmune disease; institution of steroid treatment of the
autoimmune proliferative syndrome was associated with a
parallel improvement in autistic symptoms particularly
in language [24]. Third, several additional case studies
reported in the literature also indicate positive effects of
steroids in children with R-ASD [15,24,25].
The current study constitutes a preliminary investiga-
tion based on the retrospective review of steroid treatment
of R-ASD pediatric patients at the first author’s institution.
Two important restrictions were imposed upon the retro-
spective R-ASD patient selection. First R-ASD patients
were included only if by prior sleep EEG true LKS defini-
tively had been ruled out. Although open to further evalu-
ation, it is commonly accepted clinically that an overnight
EEG sleep study and/or a daytime EEG with a significant
sleep epoch that fails to demonstrate significant sleep
activation of epileptiform discharges constitutes adequate
information to rule out LKS [9]. Second, R-ASD patients
were included in the current study if they had two sequen-
tial FMAER studies separated by at least six months and
their premedication FMAER study was read as absent or
distorted. The first author and his associates [16] previ-
ously described the utility of the FMAER in the study of
childhood language disorders (developmental dysphasia,
autism, and especially LKS). The 4 Hz FMAER produces a
scalp recorded 4 Hz sine wave steady-state evoked re-
sponse that arises in normal subjects from the bilateral
STG as determined by source analysis. It is absent or
distorted (non-sinusoidal appearance) in subjects with
language disorders involving the STG. A normal FMAER,
thus, would suggest a clinically apparent language abnor-
mality that must have arisen from a cortical language
processing disorder which originated outside of or beyond
that of the STG. Such a language disorder did not qualify
the patient for the current study. Treatment outcome
measures in the current study included bias-free, quanti-
tative assessment of change in the FMAER and internally-
developed clinical assessment scores of language and
behavior.Methods
All analyses were performed at a university affiliated
(Harvard Medical School) academic medical center
Boston Children’s Hospital (BCH). The Developmental
Neurophysiology Laboratory (DNL), under the direction
of the first author, maintains an archived comprehen-
sive database of several thousand previously studied clin-
ical patients and research subjects. This database includes
unprocessed (raw) EEG and Evoked Potential (EP) data in
addition to associated referral and clinical information.
Typically, patients had been referred for neurophysio-
logical testing in order to rule out epilepsy and/or
sensory processing abnormalities by EEG and/or EP
study. For the current project all subjects meeting
specified criteria as described below were selected from
this data base.
Subjects
Steroid Treated Autism with Regression (STAR)
The target group of study subjects selected from the
DNL database was limited to children aged 3 – 5 years old
diagnosed by academic child neurologists, psychiatrists
and/or psychologists at BCH and other Harvard affiliated
hospitals and allied medical facilities as having autism with
a historically documented period of regression at onset.
Regression was defined as the loss of age appropriate lan-
guage, communication, cognitive ability, and behaviour
determined by the referring physician and confirmed by
the treating neurologist. Patients with a slowly developing
plateau or a very slow regression over a prolonged period
of time, as opposed to an abrupt regression, were not
included in the STAR group. Furthermore, the target
group was restricted to those patients, who were clinically
treated with corticosteroids (STAR group) subsequent to
an initial neurophysiological study that showed an absent
or distorted FMAER, and who all had a second neuro-
physiological study after the treatment period was con-
cluded, i.e. after at least six and not more than 36 months.
All of the children received steroid therapy and/or other
potential treatments exclusively on the basis of the clinical
decision made by their treating neurologist in collaboration
with the parent(s) responsible for the respective patient’s
care. The treatment decisions were made much earlier
than and completely independently of the current study.
Post hoc record review revealed that none of the STAR
group children received any additional pharmacological,
behavioural, or educational interventions during the steroid
treatment period.
Non-Steroid-Treated Autism (NSA)
The comparison group of subjects was similarly selected
from the DNL database of 3–5 year old children with a
diagnosis of autism with or without a documented regres-
sion similarly established as above by an academic clinician.
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the study period (NSA) nor had they received any other
pharmacological treatment. Similarly to the STAR group
children, they had two sequential neurophysiological stud-
ies, which were separated by at least six and not more
than 36 months, each of which contained an EEG and an
FMAER [16]; the first FMAER study showed an absent or
distorted FMAER wave form. Clinical treatment of the
NSA group children as for the STAR group, was in every
case a decision between the respective treating physician
and the parent(s), responsible for the child’s care.
Subject exclusion criteria
For both the STAR and NSA study groups, exclusion
criteria included: (1) Co-morbid neurologic syndromes
that may present with autistic features (for example, Rett's,
Angelman’s and Fragile X syndromes, tuberous sclerosis,
or mitochondrial disorders); (2) clinical seizure disorders
or EEG reports suggestive of an active seizure disorder or
epileptic encephalopathy such as the Landau-Kleffner
syndrome or prominent discharge activation during drow-
siness or sleep (Note: occasional EEG spikes were not an
exclusion criterion) [26]; (3) a primary diagnosis of global
developmental delay (GDD) or developmental dysphasia;
(4) other concurrent neurological disease processes that
might induce EEG alteration (for example hydrocephalus,
hemiparesis or known syndromes affecting brain devel-
opment); (5) significant primary sensory disorders for
example, blindness and/or deafness (6); use of anticonvul-
sants (e.g. valproate, levetiracetam) at the time of the first
study (Note: Prior failed use of a medication such as
valproate did not constitute an exclusion criterion [27]);
(7) inadequate or incomplete clinical information; and (8)
a normal initial FMAER test result. All subjects in the
DNL ASD data base, who fulfilled the study’s in-and
exclusionary criteria were included in the study sample.
This yielded a study population of 20 target (STAR) and
24 comparison group (NSA) subjects.
Steroid treatment management of STAR patients
Before starting medications the treating child neurologist
presented and discussed the risks and potential benefits of
steroid medications (http://www.mayoclinic.com/health/
steroids/HQ01431) with the child’s parents. When agreed
to by the parent in each case the primary pediatrician was
contacted and agreement obtained for the management of
the necessary testing to include at a minimum: (1) Weekly
stool guaiac tests; (2) weekly (or more frequently as in-
dicated) blood pressure measurements; (3) weekly urine
glucose tests; (4) periodic blood sugar and electrolyte
assessments; and (5) willingness to manage any attendant
complications. Often Visiting Nurses performed these
tests at the patients’ homes and most parents were
successfully trained in obtaining reliable blood pressuremeasurements. All parents successfully obtained the ne-
cessary weekly weight measurements. Oral prednisolone
(Prelone™ or Orapred™) was administered by the parents
on a daily basis at 2 mg/kg/day. Dosage was occasionally
down-adjusted on the basis of minor complications.
At the monthly neurology office visits laboratory findings
were reviewed presence of complications assessed, and
clinical signs of potential increased intracranial pressure
evaluated (appearance of optic discs, quality of eye move-
ments, deep tendon reflexes, Babinski responses, suppleness
of neck, and level of consciousness). Ocular lenses were
viewed for potential development of cataracts. Language
changes from the previous visit were recorded, as measured
by use of the Clinical Language Status Questionnaire
(CLSQ), (see below). If there was no evidence of language
improvement after four months of treatment (considered
an ineffective treatment response) or if initial monthly
incremental improvement stabilized for two consecutive
months (considered a response plateau), a gradual medica-
tion taper was instituted.
Institutional review board approvals
All subject data were retrospectively evaluated under a
protocol approved by the Institutional Review Board (IRB)
Office of Clinical Investigation, BCH. The protocol was in
full compliance with the Helsinki declaration, and solely
required de-identification of all personal information
related to the already collected clinical data without re-
quirement of informed consent.
Data acquisition
Neurophysiology recording conditions data collection, and
initial data processing
All subjects’ electrophysiological data utilized in this
study were gathered by a registered EEG technologist in
the Clinical Neurophysiology Laboratory of BCH from
30 scalp channels via gold cup electrodes applied with
collodion after careful measurement. A 31st channel carried
the FMAER trial marker. A 32nd channel carried eye
movement and blink artifact information. Data were
digitized at 256 Hz after amplification by a Cardionics™
32 channel EEG amplifier (Cardionics Inc. 910 Baystar
Blvd Webster, TX 77598 USA) set to 1–100 Hz pass band.
The 30 EEG scalp channels used included the following:
FP1, FP2, F7, F3, FZ, F4, F8, FC5, FC1, FC2, FC6, T7, C3,
CZ, C4, T8, CP5, CP1, CP2, CP6, P7, P3, PZ, P4, P8, O1,
OZ, O2, TP9, and TP10 [28]. Data for the FMAER were
gathered over 5–20 minutes with additional time allowed
for rest breaks as indicated. The patient and a parent,
when behaviorally indicated, were together within view of
the technologist through a one-way mirror window in a
sound-shielded room, adjacent to the recording equipment.
Off-line, the EEG data and accompanying trial markers
were visually evaluated and epochs containing excessive
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removal from subsequent analysis. All 30 channel data were
visually inspected for EEG abnormalities and for creating
the common average reference. For the current study,
FMAER analysis was restricted to 14 active scalp electrodes:
F7, F8, T7, T8, P7, P8, TP9, TP10, F3, F4, C3, C4, P3,
and P4.
Frequency Modulated Auditory Evoked Response (FMAER)
Language comprehension requires decoding of rapidly
changing speech streams; detection of FM within speech
has been hypothesized as essential for accurate phoneme
detection and word comprehension [16]. The FMAER
was developed as a steady-state EP to assess the brain’s
response to rapid changes in the frequency modulation
(FM) of an applied auditory stimulus in extension of and
based upon the pioneering work of Green, Stefanatos and
others [15,29-33]. Recently the FMAER has been docu-
mented as showing unilateral or bilateral abnormalities in
the developmental dysphasias, Landau-Kleffner syndrome,
and in some subjects with autism. Moreover, a previously
absent FMAER has been reported to appear after success-
ful treatment of LKS. By source analysis, the FMAER has
been shown to arise bilaterally from the superior temporal
gyri (STG) of neuro-typical subjects. The orientation of
the STG source dipoles in normal subjects is such that
they each point at one end of the dipole toward the mid-
line frontal region and at the other end to the ipsilateral
inferior, posterior temporal region. The best electrodes
to record an ipsilateral signal when using the common
average reference are TP9 (left posterior-inferior temporal
for left source dipole) and TP10 (right posterior-inferior
temporal for right source dipole). Midline frontal electrodes
(FZ, FC1, FC2) usually manifest bilateral overlapping source
dipole projection. The central electrodes (C3-left central,
C4-right central) give the best view of the corresponding
hemisphere’s source dipole’s superior-anterior projection.
The FMAER may be normal, or as in pathology, of low
amplitude, distorted, or absent. In rare cases of pathology
the FMAER source location may be outside the usual
STG location and/or the source dipole may point in unex-
pected directions [16].
As previously detailed [16] the FMAER was formed
from a carrier sine wave at 1000 Hz frequency modulated
by a slower 10 Hz sine wave causing the frequency of the
carrier wave to shift (“deviate”) between 960 and 1060 Hz
at the 10 Hz rate, producing a warbling tone. The 10 Hz
sine wave was then amplitude modulated by a slower 4
Hz sine wave such that the warbling (FM modulation) was
sinusoidally turned on and off (AM modulated) at the 4
Hz rate. This process caused the 10 Hz “warbling” of the
1000 Hz sine wave carrier to be sinusoidally turned fully
on and off (100% modulation) at 4 Hz. By setting a trigger
pulse to the start of each second of 4 Hz signal, signalaveraging was performed in order to obtain the 4 Hz
steady-state FMAER - time locked to the 4 Hz AM modu-
lation of the 10 Hz FM modulation, i.e., to the turning on
and off of the FM. Between 500–1000 trigger pulses were
averaged over an epoch of 1000 msec using BESA soft-
ware (BESA GmbH, Freihamer Str. 18, 82116 Gräfelfing,
Germany). The one-second-long steady state FMAER
tracing from neurotypical subjects manifests a 4 Hz sine
wave. The stimulus’ sound pressure level was held at ap-
proximately 78db Sound Pressure Level (SPL), measured
at the ears and was delivered either by earphones or by
nearby bilateral speakers depending upon the environment
and subject preference and tolerance. At time of clinical
study, FMAERs were initially formed from successive thirds
of all stimuli which, when separately evaluated, allowed as-
sessment of response consistency. If responses were similar
across all three thirds, a global average was formed for in-
terpretation. If such consistency was not observed, more
data were collected to improve the signal to noise ratio.
The Chirp2™ Signal Generator (Mind Spark Inc., 172
Washington St, Newton, MA 02458 USA), a small stand-
alone battery operated device, was employed to perform
all aspects of the FMAER from signal generation through
trial marker formation.
FMAER data were viewed on BESA software using the
common average reference since mastoid/ears references
induce artifactual spatial localization. Each subject’s
response was visually reviewed for both hemispheres.
The normal response consisted of a clear 4 Hz sine wave.
An abnormal response varied from absence of any obvious
response to a distinctly non-sinusoidal response sug-
gesting a mix of multiple frequencies. In order to quantify
responses for analytic purposes power spectral analysis was
performed on the FMAER traces (BESA software) and the
resulting 4 Hz spectral value was utilized as the primary
quantitative measure of the brain’s response [16].
Noise analysis
The steady state 4 Hz FMAER when ‘absent’ by visual
inspection rarely presents as a simple flat-line display.
Typically a low amplitude epoch of apparently random
noise is visualized that does not appear to contain an
obvious 4 Hz component. Such a noisy response reflects
four possibilities: (1) There is no 4 Hz response and the
noise reflects incomplete signal averaging; (2) There is a
low amplitude 4 Hz response which is masked by noise
from incomplete signal averaging; (3) The response is
distorted showing frequencies adjacent to 4 Hz (side-band
distortion) which causes the response to appear non-
sinusoidal or noisy; or (4) A combination of the above
three possibilities might be identified. In order to assess
these possibilities in keeping with established techniques,
a plus-minus averaging technique was utilized “in which
measurements from every other trial are inverted prior to
Duffy et al. BMC Neurology 2014, 14:70 Page 6 of 17
http://www.biomedcentral.com/1471-2377/14/70creating the averaged result which removes the consistent
signal component by the alternating addition and sub-
traction (and) the noise component is the same as that
produced by the standard average [34] (page 61)”. By
creating the root-mean-square voltage (Vrms) of a plus-
minus average one can compare this Vrms to the Vrms of
the standard average. If there is no evoked response the
standard and plus-minus averages typically show nearly
the same Vrms values. If there is an evoked response of
any sort the standard average typically produces a Vrms
greater than does the plus-minus average. Since the
plus-minus and the standard averages have the same
noise distribution, spectral analysis of the plus-minus
average can be subtracted from that of the standard
average in order to estimate the spectral distribution of
signal added in response to the stimulus. An advantage
to the plus-minus technique is that noise is estimated
on the very same EEG segments that are averaged in
order to produce the FMAER. Software was developed
in-house to perform plus-minus averaging and to create
Vrms data.
For the current study noise analysis was limited to the
STAR population’s FMAER data from the two left hemi-
sphere electrodes (TP9 C3), which manifested the most
significant pre- and post-treatment FMAER difference at
4 Hz (Table 1). The locations roughly correspond to the
maximum scalp projection of the superior and inferior
aspects of the typical FMAER dipole generator located
in the left superior temporal gyrus [16]. At the time of
signal averaging, the EEG was additionally band pass
filtered from 1–12 Hz. An estimate of the FMAER response
was taken at 4 Hz and an estimate of ‘side-band noise’ was
taken as the average of the spectral data at 2, 3, 5, 6, and 7
Hz at both study points. To start, the Vrms of the standardTable 1 Noise analysis of the FMAER for Time 1 and Time 2, S
(a) Time one pre-treatment data: Standard vs. Plus-Minus FMAER
Electrode Vrms 4 Hz 5
T p T p
C3 +3.84 0.0012 +3.77 0.0014
TP9 +3.24 0.0046 +3.43 0.0030
(b) Time post-treatment data: Standard vs. Plus-Minus FMAER
Electrode 4 Hz 2, 3, 5, 6, 7 Hz
T p p
C3 +5.96 0.0000 n.s
TP9 +5.94 0.0000 n.s




TP +3.69 0.0017average and plus-minus average for the first time point
(before steroids) data were compared to determine if any
added component was evident in the standard average.
Next, and separately for the first and second study time
point, spectral analysis was performed independently on
the standard FMAER average as well as on the plus-minus
average. The plus-minus average spectral results were
then subtracted from the standard spectral results at each
study point separately. The resulting spectral difference
result estimated the portion of spectral signal attributable
to the stimulus, after removal of the best estimate of
spectral background noise.
Subjective evaluation of EEG abnormality
All first and second EEG studies were visually reassessed
by a pediatric electroencephalographer blinded to subject
history and group identity. All EEGs were reviewed in
randomly selected order with respect to group and study
order. Each EEG was scored as showing in ascending
order of abnormality (if present): paroxysmal sharp theta
sharp waves, and spike or spike wave discharges. After this
‘blinded’ estimation was completed, EEG results were
sorted into first and second EEG study order, without
group identity; subsequently the electroencephalographer
compared each subject’s two sequential EEGs and clas-
sified their scores as showing ‘worsening’ ‘no change’,
or ‘improvement’ between the first and second study. For
example, a subject showing ‘spikes’ on the first study and
‘no spikes’ on the second study would be considered as
‘improved’.
Language assessment STAR Group
STAR group subjects were followed by their child neu-
rologists using a clinical language assessment referred toTAR group
Hz 6 Hz 2, 3, 7 Hz
T p T p p
+2.97 0.0083 +2.39 0.0278 n.s
+2.26 0.0388 n.s. n.s
Table 2 Clinical Language Status Questionnaire (CLSQ)
Expressive score Receptive score
10 Appears normal 10 Seems normal
9 Normal but dysarthric 9 Nearly normal receptively
9 Nearly normal expressively 9 Responds to incidental language




8 Responds to two part requests
8 Produces meaningful 1–2
word phrases
6 Responds to one part requests
7 Produces single words on
own initiative
4 Responds to words without
gestures
5 Mimics words strings
without meaning
2 Responds to words with gestures
4 Produces meaningless words 1 Responds better to voices than
to noises
3 Only sings words 0 Responds better to noises than
to voices
1 Produces word-like meaningless
sounds
0 Acts deaf
1 Babbles, no words
0 Makes noises, or only screams
0 Mute
Receptive Language Scoring
Ask the parent(s): “In the course of the last month what is the most complex
spoken language, given without helpful gestures, that you know your child
understands and may respond to but need not respond to every time.”
Ask for discrete examples and match to 11 shown possibilities. We are after
the highest level response of which the parents are certain. Parents may be
shown the alternative choices but not the associated scores.
Expressive Language Scoring
Ask the parent(s): “In the course of the last month what is the most complex
spoken language you have heard your child produce.” Again we are after the
highest level of language production of which the parents are certain. Match
to one of the 14 shown possibilities. Parents may be given the alternative
choices but not the associated scores.
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which was developed in-house well prior to the current
study. It is as yet unpublished. The assessment was de-
signed to assist pediatric neurologists involved in the
pharmacological treatment of neurological disorders,
in estimating language progress or lack thereof - from a
child’s parent(s)’ report and the clinician’s direct assess-
ment at the time of a clinical visit. It involves evaluation of
both the child’s current best expressive and receptive lan-
guage performance. In the current study, documentation
of lack of response improvement or plateau, along with
assessment of medical complication(s), constituted the
primary evidence used for treatment discontinuation.
Table 2 shows the CLSQ score definitions for expressive
and receptive language performance. The term ‘Appears
normal’ (Table 2) was defined as the clinician’s and
family’s report of normal, age-appropriate speech. None
of the children in this study received this score. ‘Appears
nearly normal’ was defined as context and age appropriate
speech with evidence of mispronunciations, poor or odd
word choice, unusual fluency or unusually sparseness, un-
usual grammatical errors such as errors in tense , pronoun
gender match and/or pluralization, and/or requirement of
adult speech simplification in order to assure comprehen-
sion relative to age expectancy. The difference between
‘short meaningful 1–2 word phrases’ and “meaningful
3+ word phrases’ is self-explanatory. Although many
well developed language tests exist, as documented by the
American Speech-Language-Hearing Association (http://
www.asha.org/assessments.aspx), most tend to be detailed
yet too coarsely grained to capture this population’s limited
language range. They are also typically too time-consuming
for repeated administration by neurologists during recur-
ring, clinical check-in visits. In contrast, the CLSQ may be
completed in less than ten minutes. An additional advan-
tage of the CLSQ for the current study was its compre-
hensiveness in capturing the full - while limited - range of
language change observed in this patient population.
Parents are shown short phrases (without the numerical
scores) and asked to identify their child’s current relevant
expressive and receptive status. The neurologist stands by
to clarify, assist, and help resolve two caregivers’ divergent
opinions. Neurologists using the CLSQ are sensitive to the
language performance definitions in question. The study
subjects’ CLSQ score assignments occurred without prior
knowledge of the current study.
Language assessment NSA Group
Since the CLSQ was not employed for those pediatric
populations who did not receive pharmacological inter-
vention(s) the NSA group subjects lacked the CLSQ
scores. Their language status was estimated retrospectively
on the basis of the clinical assessment of expressive and
receptive language abilities performed within the standardcomprehensive neurological evaluation included in every
office visit. The clinical reports closest in time to the two
neurophysiological studies were utilized to score separ-
ately receptive and expressive language performance and
to assign a change score from the initial to the second
visit. The change score was scaled from minus (−) 2 to
plus (+) 2 as follows: −2 =marked worsening; −1 = some
worsening; 0 = no change; +1 = some improvement;
+2 = marked improvement. In the case a clinician failed
to distinguish between receptive and expressive language
performance the same score was assigned to both categor-
ies. Failure to comment on language performance at all re-
sulted in exclusion of the subject from consideration for
the current study. No subjects were excluded on this basis.
NSA subjects’ language scoring was performed well before
the current study was undertaken and without knowledge
as to which particular subject might be included in the
study. Scorers had no knowledge of the current study’s
goals or design the future group status of subjects, or the
Table 3 DSM-IV Criteria for Autism Disorder, and Scoring
Criteria: A subject must have a total of six (or more) items from A1, A2, and A3. with at least two from A1
and at least one each from A2 and A3
A1. Qualitative impairment in social interaction, as manifested by at least two of the following:
A1a) Marked impairment in the use of multiple nonverbal behaviors such as eye-to-eye gaze, facial expression, body
postures, and gestures to regulate social interaction.
A1b) Failure to develop peer relationships appropriate to developmental level
A1c) Lack of spontaneous seeking to share enjoyment, interests, or achievements with other people (e.g., by lack of
showing, bringing, or pointing out objects of interest)
A1d) Lack of social or emotional reciprocity
A2. Qualitative impairments in communication as manifested by at least one of the following:
A2a) Delay in, or total lack of, the development of spoken language (not accompanied by an attempt to compensate
through alternative modes of communication such as gesture or mine)
A2b) In individuals with adequate speech, marked impairment in the ability to initiate or sustain a conversation with
others (omitted from scoring – see text)
A2c) Stereotyped and repetitive use of language or idiosyncratic language
A2d) Lack of varied, spontaneous make-believe play or social imitative play appropriate to developmental level
A3. Restricted repetitive and stereotyped patterns of behavior, interests and activities, as manifested by at least one
of the following:
A3a) Encompassing preoccupation with one or more stereotyped patterns of behavior and restricted patterns of
interest that is abnormal either in intensity or focus
A3b) Apparently inflexible adherence to specific, nonfunctional routines or interests
A3c) Stereotyped and repetitive motor mannerisms (e.g., hand or finger flapping or twisting, or complex whole-body
movements)
A3d) Persistent preoccupation with parts of objects
B. A subject must show delays or abnormal functioning in at least one of the following areas, with onset prior to
3 years:
B1) Social interaction
B 2) Language as used in social communication
B3) Symbolic or imaginative play
Graded scoring – each item: (Item A2b omitted)
0 = absent
1 = possibly or very mildly present
2 = definitely present
3 = a very dominant characteristic
Overall score = average of 14 scored items
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many children’s language reports were scored retrospect-
ively as were declared eligible for inclusion in the study.
Behavioral assessment
The DSM-IV criteria for Autistic Disorder (299.0) [35]
aside from employment for diagnosis, were scaled in
terms of severity for each STAR group child and the
sum of the scaled scores was assigned as behavioral
score. The direction of scaling was defined such that
the higher the score was, the more severe the behavioral
manifestations of ASD were. The symptom items and
scaling are described in Table 3. Note, that item A2b) was
omitted from the total score since none of the study
children demonstrated “adequate speech”. Summed scaleditem scores were assigned in order to quantify behavioral
change in analogy to language change. For the current
study scores were selected for the office visit nearest to
the first and the second EEG/FMAER studies respectively.
Scorers had no knowledge of the current study’s goals or
design, the future group status of subjects, or the subjects’
FMAER results. The NSA group subjects lacked the
DSM-IV based behavior scores.
Data analysis
The BMDP2007™ statistical package (Statistical Solutions
Stonehill Corporate Center, Suite 104, 999 Broadway,
Saugus, MA 01906 USA) [36] was utilized for standard
statistical analyses. Program 2D (P2D) was used for data
description, Program 3D (P3D) for paired t-tests, and
Table 4 Group demographics
STAR group (n = 20) NSA group (n = 24) t-test p
Age at first study (years) 3.909 +/− 1.248 4.522 +/− 1.800 1.29 n.s.
Time between studies (years) 2.136 +/− 1.609 1.904 +/− 0.989 0.49 n.s.
Age at regression (months) 18.925 +/− 9.928
Length of regression (weeks) 20.053 +/− 12.70
Length of treatment (months) 9.125 +/− 3.26
Gender 18 males, 2 females 18 males, 6 females n.s.
Handedness 18 right, 2 left 23 right,1 left n.s.
Subjects with history of regression (n) 20 of 20 7 of 24 0.0001
Table 5 Time 1 to Time 2 difference of the 4 Hz FMAER,
paired t-tests
STAR group NSA group
Electrode Mean diff. T p Mean diff. T p
F3 47.18 2.57 0.0188 16.83 1.17 n.s.
C3 24.15 3.02 0.0070 15.45 1.35 n.s.
P3 10.49 1.25 n.s. 3.23 1.04 n.s.
F7 3.38 0.51 n.s. 3.26 0.72 n.s.
T7 15.49 2.83 0.0106 6.31 0.83 n.s.
P7 65.08 2.37 0.0283 24.69 1.71 n.s.
TP9 56.91 3.31 0.0037 31.77 1.78 n.s.
F4 64.31 2.41 0.0260 20.89 1.21 n.s.
C4 22.66 3.12 0.0056 13.48 1.15 n.s.
P4 10.52 1.96 n.s. 3.12 0.59 n.s.
F8 18.47 1.44 n.s. 8.02 0.95 n.s.
T8 30.60 1.87 n.s. 1.08 0.07 n.s.
P8 77.83 2.86 0.0100 35.87 1.36 n.s.
TP10 83.49 2.41 0.0260 36.03 1.51 n.s.
T = t-test score; p = probability; n.s. = not significant;
Mean Diff. = mean of pre to post difference of 4 Hz FMAER spectral power, μV2/Hz.
For electrode locations see Figure 1.
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exact test for 2 × 2 tables utilized an online Graph
Pad™ program. Fisher’s exact test for 2 × 3 tables with




The STAR group’s sample size was 20 and the NSA
group’s 24 subjects (see Table 4 for demographics). The
means and standard deviations (SD) of the ages for the
two groups at the time of the first neurophysiologic
study were 3.91 (1.25) and 4.52 (1.80) years respectively
and the mean and SD time between the first and second
studies was 2.14 (1.61) and 1.90 (0.99) years respectively.
Neither age at first study nor interval between studies
differed statistically between the two groups. All STAR
group subjects manifested language and behavior regression
sufficiently abrupt to allow parents to date onset to within
a few days to maximally a few weeks. Mean and SD STAR
group age at regression onset was 18.93 (9.93) months
and mean length of regression to a point of relative stability
was 20.05 (12.7) weeks. Mean and SD of steroid treatment
length was 9.125 (3.26) months with a range from 4 to 14
months. The two groups did not statistically differ by Fisher
Exact test regarding gender or handedness (Table 4).
By definition the STAR group was entirely (20 of 20)
comprised of children with regressive autism. The NSA
group contained, by chance, several children with regressive
autism (7 of 24) (Table 4). This difference was significant by
Fisher’s Exact test, p = 0.0001.
Change in FMAER between time 1 and time 2 subsequent
to steroid treatment
As shown in Table 5 for the STAR group nine of 14
electrode measurements of the FMAER’s 4 Hz response
manifested a significant change, measured by matched-
paired t-test, between study values before and after steroid
therapy. The biggest change was identified at the left
posterior-inferior temporal electrode TP9 (p = 0.0037).
In contrast, not one of the 14 analogous FMAER spectralmeasures compared between time 1 and time 2 for the
NSA group was statistically significant. All NSA group
members demonstrated an increase in 4 Hz magnitude
from study 1 to study 2; this did not exceed the expected
change with age. None of the NSA group’s study 1 to
study 2 differences was significant at any of the electrode
sites measured.
Figure 1 illustrates an example of one STAR group
subject’s relevant FMAER and associated spectral changes
from before to after steroid administration: Note the
absence of a clear 4 Hz sine wave following response
before treatment in contrast to the excellent 4 Hz sine
wave following response after treatment. The ‘before
treatment’ fast Fourier transform (FFT) power spectrum
response furthermore illustrates that the input 4 Hz
stimulus appears at the cortex and demonstrates power
at many different frequencies aside from the expected
Figure 1 FMAER and corresponding FFT, before and after steroids in regressive autism. 4 Hz FMAER waveform data are shown within
schematic ovals in vertex view with nose up, and left side of scalp to image left. The corresponding power spectra are shown to the immediate
right. The top waveform and FFT displays were obtained prior to steroid administration. The bottom, corresponding displays were obtained after
steroid administration. The vertical arrow to the lower left of each image represents 10 μV and the horizontal arrow beneath represents one
second waveform length. The labels adjacent to the FMAER waveforms correspond to the standard EEG electrode 10–10 naming convention.
Twenty-four electrodes’ waveforms are shown. The FFT power spectral data horizontal axis covers the 0–30 Hz range. Note the near absent 4 Hz
FMAER waveform response before and excellent 4 Hz waveform response after steroid administration. Note the spread of spectral power over
many frequencies in the FFT display before (above) which represents a distorted response. This contrasts to the nearly perfect 4 Hz response after
steroid treatment (below) which shows little spectral spread (little distortion). For the vertex view display, waveforms are shown overlying their
standard ‘10-10’ locations. For the FFT graphs, channel order from top to bottom is: F3, F4, C3, C4, P3, P4, O1, O2, Fp1, Fp2, F7, F8, T7, T8, P7, P8,
FT9, FT10, TP9, TP10, Fz, Cz, Pz, Oz. The common average reference is utilized for the displayed data (a reference free or ‘rfr’ technique) [10].
Abbreviations: A = anterior, P = posterior, L-left, R = right, FMAER = 4 Hz frequency modulated auditory evoked response, FFT = fast Fourier transform -
power spectrum analysis shown as μV2/Hz, μV =microvolt, Hz = Hertz or cycles per second.
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Table 7 Time 1 to Time 2 CLSQ difference scores for STAR
group
Language Mean diff. t p
Receptive 4.80 7.32 0.00001
Expressive 4.10 6.17 0.00001
t = t-test score; p = probability; n.s. = not significant; Mean Diff. = mean of
pre- to post difference of CLSQ difference scores.
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frequencies in output to a single frequency input rep-
resents response distortion [37]. It is visualized in the
FMAER waveforms by their non-sinusoidal appearance
and in the FFT by the spread across the spectrum away
from the primary 4 Hz driving frequency. Note how-
ever, that after steroids the FMAER waveform was
sinusoidal at 4 Hz and the FFT showed a well-aligned
response at the expected 4 Hz frequency without spec-
tral spread, i.e. without distortion. All STAR subjects
uniformly demonstrated such reduction of distortion after
steroid treatment, while this change was not observed in
the NSA group.Noise analysis
As summarized in Table 1 for the first study point, as
shown in Table 1-(a), there was significantly increased
Vrms in the standard average as compared to the plus-
minus average at both electrodes selected (TP9 p ≤ 0.0046,
C3 p ≤ 0.0012). Also at the first study point, both TP9 and
C3 demonstrated significantly increased 4 Hz activity for
the standard average as compared to the plus-minus aver-
age (TP9 p ≤ 0.0030, C3 p ≤ 0.0014). However, there was
also spuriously increased 5 Hz activity (TP9 p ≤ 0.0388,
C3 p ≤ 0.0083) and 6 Hz (C3 p ≤ 0.0278). These findings
indicate that at the first study point in addition to an
unexpected 4 Hz response there was also evidence of a
strong noise response at frequencies other than 4 Hz,
namely at 5 Hz and 6 Hz. In contrast, at the second study
point, as shown in Table 1-(b), there was an even stronger
4 Hz response (TP9 p ≤ 0.0017, C3 p ≤ 0.0072), and more-
over, this response now showed no evidence of significant
accompanying noise responses at other frequencies. The 4
Hz FMAER response amplitude increase from time 1 to
time 2, as shown in Table 1-(c) remained statistically
significant when corrected for noise at approximately
the same statistical significance level as shown in Table 5
for the uncorrected response.Table 8 Time 1 to Time 2 Change in language scores
between first and second study for STAR and NSA groups
Group Better NoDiff Worse Fisher exact
Receptive languageChange in EEG abnormality between STAR and NSA Groups
As demonstrated in Table 6 there was no significant differ-
ence across time points in the type of EEG abnormalities
identified by visual inspection between the STAR and
NSA groups by Fisher’s exact test. Thus, the children’s
EEG, in contrast to the FMAER, failed to show any effect
associated with of time or treatment.Table 6 Difference between groups in EEG change from
Time 1 to Time 2 EEG change summary
Group Worse No change Improved by Fisher 2x3 exact test
STAR 7 10 3 n.s.
NSA 4 12 8Change in language function
As demonstrated in Table 7 the STAR group showed a
significant difference in the mean CLSQ scores from time 1
to time 2; receptive and expressive language functions both
showed a highly significant score increase i.e. improvement.
For the NSA group the mean of the language change score
for receptive language was 0.167 and for expressive
language 0.542; neither reached statistical significance.Number of subjects showing change in language function
Negative language change scores indicated language wors-
ening a score of zero indicated lack of change, and positive
scores indicated language improvement from the first to
the second visit. Table 8 shows two 3 × 2 Fisher’s exact tests
for the number of subjects showing change (improvement,
no change, or worsening) separately for receptive and
expressive language. The results revealed improvement
for a significantly higher number of STAR group subjects
as compared to NSA group subjects, both in terms of
receptive as well as expressive language.Language change for NSA subjects with and without
history of regression
Table 9 compares receptive and expressive language change
scores across the two time points for the number of NSA
group subjects who had a history of regression with those
who did not show regression. As 2 × 2 Fisher exact test
subject numbers per cell were small, subjects who showed
no change or worsened were collapsed into one group. The
results revealed that the number of children without a
history of regression did not statistically differ in terms
of language change over time from the number of subjects
who did not show regression.STAR 17 3 0 P≤ 0.0002
NSA 6 16 2
Expressive language
STAR 17 2 1 P≤ 0.0031
NSA 10 13 1
p = probability; NoDiff = no difference.
Table 9 Time 1 to Time 2 Change in language scores for
NSA group when comparing the patients with and
without history of regression
Group Better NoDiff/worse Fisher exact
Receptive language
NoRegr 3 14 n.s.
Regr 3 4
Expressive language
NoRegr 7 10 n.s.
Regr 3 4
Table 11 Multiple regression, NSA group: 14 FMAER
differential FFT scores separately predict receptive and
expressive language differential scores
Variable entered R p F to enter
Receptive
P4 0.5909 0.01 11.81
Expressive
P4 0.5288 0.01 8.54
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scores for the STAR and NSA Groups separately
Table 10 shows the STAR group’s result of the stepwise
multiple regression analysis performed in order to explore
the relationship between changes in the FMAER and
changes in language performance separately for receptive
and expressive language across each subject’s two time
points. The result was highly significant with just a single
FMAER variable chosen for receptive language (FMAER
at C3 left central region) and a single variable chosen for
expressive language (FMAER at T7, left mid- temporal
region). The first step in both analyses showed many of
the 14 independent variables’ significant correlation with
the dependent language measure (receptive 8/14, expressive
9/14 at F ≥ 4.0 to enter). However, at the second step after
the removal of the effect of the first independent variable
from the remaining 13 independent variables, none of the
variables reached the F level ≥ 4.0; therefore none was
chosen. This indicates suppression of 13 variables by the
first variable chosen which in turn demonstrates that, as
expected, that all 14 independent variables contain similar
information. Table 11 shows the analogous result for the
NSA group. Again the result was highly significant with a
single variable (FMAER at P4, right parietal lobe) chosen
for both the receptive and the expressive language scores.
Again there was only one step, since the first variable
chosen suppressed the remaining 13 variables due to the
high shared information, i. e. high correlation among the
variables.
Thus although similarly significant multiple FMAER-
language regression scores were noted for both groups,
the best FMAER-language correlation for the STAR groupTable 10 Multiple regression, STAR group: 14 FMAER
differential FFT scores separately predict receptive and
expressive language differential scores
Variable entered R p F to enter
Receptive
C3 0.6296 0.01 11.82
Expressive
T7 0.6134 0.01 10.86manifested itself in two left hemisphere electrodes (T7
receptive, C3 expressive) whereas for the NSA group the
best language correlation manifested itself in a single right
hemisphere electrode (P4 right parietal, for both, receptive
and expressive).
Change in behavioral criteria for autistic disorder
STAR group
As shown in Table 12 the STAR group showed a highly
significant reduction in the DSM-IV ASD scaled symp-
tom summary scores when comparing the before and
after treatment scores.
Complications of steroid treatment STAR group
As shown in Table 13 almost all STAR group subjects,
as anticipated, demonstrated Cushingoid appearance and
experienced weight gain associated with enhanced appetite.
For all subjects weight and appearance returned to normal
within several months of discontinuation of steroids.
Excessive weight gain was typically managed successfully
by parent-guided dietary restrictions, especially reduction
of carbohydrate intake. Half of the population initially
experienced behavioral worsening, typically irritability. This
was usually successfully managed by a slight reduction of
steroid medication. When severe (two subjects), risperdone
therapy was used successfully without concurrent language
deterioration. Only one subject required medical treatment
for hypertension; the others responded to slight steroid
reduction. Any observed GI bleeding and elevated serum
calcium spontaneously normalized without need for inter-
vention. The single urinary tract infection observed was
easily treated with antibiotics. Two subjects with sleep dis-
turbances (frequent wakening) were successfully treated
with melatonin. Many subjects experienced cold weather
associated upper respiratory tract infections without need
for any special medical intervention. Two of the 20 subjects
manifested slight language regression after conclusionTable 12 Time 1 to Time 2 DSM-IV Score difference, STAR
group
Group Average DSM-IV Score d.f. T p
t-test of mean of 14 scores (see text and Table 3)
Before 2.0677 38 7.261 0.00001
After 0.9857
Table 13 Treatment complications, STAR group
Cushingoid appearance: 18/20 Weight gain: 19/20
Significant hypertension: 2/20 High serum calcium: 1/20
GI bleeding: 1/20 Excess urine glucose: 1/20
Mild behavior disorder: 7/20 Severe behavior disorder: 3/20
Sleep disorder: 2/20 Infection: 1/20
Regression: 2/20 Cataracts 0/20
Duffy et al. BMC Neurology 2014, 14:70 Page 13 of 17
http://www.biomedcentral.com/1471-2377/14/70of the steroid taper. Both responded well to 1–2 months
of re-treatment using a pulse steroid dosing protocol
(50% of prior weekly dose given one day a week for 1–2
months). None of the subjects developed cataracts. By
approximately one year after cessation of steroid therapy
those 17 subjects (Table 8) STAR subjects who had demon-
strated clinical language improvement maintained and/or
further improved their performance after cessation of
treatment. The three subjects who had not responded
well, manifested no significant change at the one-year
follow-up point. However, this apparent stability was
documented only by parent response.
Discussion
The overall goal of this study was to identify by retrospect-
ive data analysis, quantifiable evidence supportive of benefi-
cial effects of adrenal corticosteroid (prednisolone) therapy
on brain, language and behavioral function of children with
a history of sudden autistic regression (R-ASD). Such
evidence, while retrospective, nevertheless might serve
to strengthen sufficiently the existing anecdotal reports
for such salutary effects [15,24,25], in order to potentially
justify a future prospective randomized trial of steroid
treatment for R-ASD. To this end a large clinical patient
database of children with a diagnosis of autism spectrum
disorder (ASD) was searched for pertinent target subjects
who met the criteria for regressive autism, were between
the ages of 3 and 5 years at the time of their first FMAER
study, had an absent or distorted initial FMAER study, re-
ceived steroid treatment (STAR group), and had a second
FMAER study performed after steroids were discontinued.
Following identification of the target group subjects, a
non-steroid-treated ASD comparison group was identified.
These were comparable-age children also with an initial ab-
sent or distorted FMAER study and with a second FMAER
study performed between 6 and 36 months later, yet not
treated with steroids (NSA group). Twenty target group
children (STAR) and 24 comparison group children (NSA)
were identified (Table 4). The NSA group children were
followed by their clinicians in the same overall time span
as the STAR sample. Additionally available data aside
from the two FMAER studies included for the STAR
group receptive and expressive language scores based
on a clinical assessment (CLSQ) specifically developed
for pediatric ASD patients who receive pharmacologicaltreatments, as well as DSM-IV ASD total number of
symptom scores. For the NSA group receptive and expres-
sive language scores derived from neurologists’ clinical
notes were calculated for the two clinical visits temporally
closest to the two FMAER tests utilized. All scores were
available and had been entered into the clinical database
prior to study design and analysis.
The investigation’s first and most important specific
goal was to compare by means of objective spectral
analysis, potential changes in the 4 Hz FMAER steady-state
response between the first and second study point for each
of the two subject groups separately. Results showed strik-
ing differences in change between the two populations
(Table 5). For the STAR group, 9 of 14 electrodes showed
markedly increased second-study 4 Hz response magni-
tudes with maximal effect in the left inferior-posterior
temporal electrode, TP9 (p ≤ 0.00037). In contrast the NSA
group failed to manifest any significant change in 4 Hz
spectral power at any of the 14 electrodes Thus, the steroid
treatment appears associated with a significant in-
crease in the specific FMAER stimulation elicited 4
Hz response amplitude of the superior temporal gyri
(STG) in both hemispheres of the study children with
regressive autism. Additionally, the FMAER response
distortion present at the first study point of the STAR
group was absent at the second study point (Table 1)
Thus, the STAR group demonstrated both higher am-
plitudes and a less distortion in the FMAER after
steroid treatment.
Not all electrodes manifested a significant increase in
the 4 Hz response to steroids in the STAR group (Table 5).
The reason for this appears to lie in the fact that the
FMAER may be modeled as a single dipole within each
STG. These dipoles have both a specific physical location
and a specific orientation. What is seen on the scalp is the
projection of the dipole source from each STG upon the
overlying scalp such that the scalp response magnitude
reflects the dipole orientation and location which varies
slightly among subjects. By including 14 distributed scalp
locations seven per hemisphere, one may conclude that
failure to demonstrate any significant changes in the NSA
group did not arise from a failure to record over a ‘hot’
scalp region [16], but from the lack of a significant response
change over time.
As Figure 1 illustrates the before and after spectral
plots demonstrate that the subjects receiving steroids
showed not only a significant increase in magnitude of
the appropriate 4 Hz FMAER response but simultaneous
that distortion products in the form of other than 4 Hz
response components evident in the pre-medication FFT
plots were significantly reduced. In their well-known
speech quantification work, Wu and Pols [27] note that
“…in many situations the speech quality is not satisfactory,
often due to factors related to the transmission of the
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sion there is a variety of factors influencing the quality
of speech, such as: a limitation of the frequency range
or the dynamic range, noises, echoes, and other (analog
or digital) distortion components.” On the basis of the
current study’s results it appears reasonable to speculate
that distortion may additionally occur within the central
auditory pathway of the listener as visualized by the FMAER
at the level of the STG.
It is hypothesized that language regression in autism
may result from the development of dysfunction in the
specific STG systems that are needed to accurately and
cleanly detect rapidly changing spectral information within
the acoustic stream. Children with R-ASD are not deaf or
‘hard-of-hearing’ per se; they often clearly identify even very
soft novel sounds. The problem appears to reside in the
auditory distortion that occurs within cortex devoted to
language processing. This distortion appears to be at least
partly reversible with steroid therapy.
The study’s second goal was to determine whether the
significant FMAER improvements might be related to
steroid-based suppression of presumed-to-be minor ab-
normalities in the children’s EEGs as observed by visual
inspection. Note that neither group demonstrated frank
epileptiform transients such as spikes or spike and wave
patterns. The EEG change rankings did not differ between
the two groups (Table 6). Additionally the EEG changes in
the STAR group included both EEG improvement and
EEG worsening. These findings emphasize that there ap-
pears to be little evidence for a physiologically meaningful
steroid effect on EEG. This is an important finding that
runs contrary to the assumption made in Landau-Kleffner
syndrome, namely that both language and FMAER im-
provements with steroids result from suppression of
frequent spike discharges within the STG [16]. What
may be common to R-ASD and LKS children’s brains is
dysfunction of the STG. However, the dysfunction need
not necessarily be accompanied by spike discharges. It
may, none-the-less, be ameliorated by steroids.
The third goal was to compare changes in clinical-
rating-based language scores between the first and the
second study. As shown in Table 7 the STAR group showed
highly significant improvement in the language ratings
between time study 1 and 2; the improvement was com-
parable for both the receptive and expressive language
ratings. Moreover significantly more STAR group subjects
(17/20) than NSA group subjects showed improvement
(6/24 ‘better’ receptive, and 10/24 ‘better’ expressive). These
data suggest that steroid treatment may be associated with
improvement in language and that more subjects who
receive steroid treatment may show such improvement
than subjects in the non-treated group.
In order to rule out the possibility that regressive autism
spontaneously improves with time estimated languagechange of the seven NSA group children with histories
of regression was compared to that of the 17 NSA group
children without such a history of regression (Table 4).
Although the small population size precludes a definitive
answer, there was no significant difference between the
two NSA subpopulations for receptive or for expressive
language ratings (Table 9). Thus, spontaneous NSA group
improvement of language in the regressive autism subpop-
ulation was not observed.
The fourth goal was to explore the possible relationships
between changes in 4 Hz spectral responses at all electrodes
and the language ratings change scores (Table 7) for
receptive and expressive language separately. The STAR
group (Table 10) showed a strong correlation between re-
ceptive language and the FMAER at the left central region
(C3) and between expressive language and the FMAER in
the left mid temporal region (T7). It appears clinically
meaningful that STAR group language improvement was
more evident in the left hemisphere as the left hemisphere
is typically the dominant hemisphere for language. Given
that the scalp FMAER data are highly inter-correlated and
reflect activity at the level of the STG, the difference in
the scalp location of maximal effect for correlations with
receptive and expressive language is curious. It is possible
that slightly different regions of the STG are responsible
for expressive and receptive language functions resulting
in subtle differences in the dipole source orientations
or locations and correspondingly different in patterns
of scalp projection. This is an area for future exploration.
For the NSA group (Table 11) a strong correlation was
found between the right parietal (P4) region and both the
receptive and the expressive language scores. It is curious
that the typically non-language dominant right hemisphere
STG maximally correlated with NSA group language func-
tion. This may reflect relatively greater dysfunction within
the left hemisphere in this group. These findings are limited
by the clinical rating measures of language employed in
this study. Formal language testing with standardized
assessments will be required to substantiate these pre-
liminary findings.
The fifth goal was to determine the level of behavioral
improvement within the steroid-treated group. The scaled
DSM-IV symptom summary scores demonstrated a highly
significant improvement after steroid treatment (p ≤
0.00001) (Table 12) Thus steroid treatment may be as-
sociated with behavioral improvement.
Finally the study’s sixth goal was to weigh the compli-
cations of steroid administration against their potential
benefits (Table 13). Overall, almost all steroid-treated
subjects gained weight. Working with families to coun-
teract increased appetite and associated weight gain was a
dominant clinical task in patient management. Behavior
and sleep disorders were readily managed pharmaco-
logically. The two subjects, who experienced behavioral
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with a short period of pulse dosing. There were few serious
complications although the process clearly increased the
task of managing the child’s well-being and health for the
parent and should only be undertaken with comprehensive,
detailed understanding of the ramifications involved in
such a significant medication trial. The most frequent
management tasks for the parents were: (1) the constant
need to monitor food intake in order to avoid weight
gain which in turn might facilitate development of second-
ary hypertension; and (2) the difficulty in managing the
child’s behavior.
It is unclear at this point how steroids might function
to improve language and behavior in regressive autism.
Aside from a relatively sudden clinical onset the current
study fails to establish similarities between R-ASD and the
Landau-Kleffner syndrome and other epileptic syndromes.
Some have suggested an immune process, possibly initiated
by outside factors that challenge the immune system. Only
two of the 20 families in the STAR-group suggested regres-
sion onset in close relationship to inoculations (MMR, in-
fluenza vaccination). Extensive studies reported in the
literature have failed to identify a clear association between
autism (including R-ASD) and protective immunizations
[38]. Eighteen of the 20 current study’s R-ASD STAR group
subjects provided no clinical information as to possible
trigger events. Although a question of importance, the
current data do not shed light on regression etiology.
As reviewed by Kurian and Korff [18] corticosteroids,
although not necessarily a first-line treatment, have been
used with some success in a number of epileptic syndromes
aside from LKS. These include infantile spasms, Doose
syndrome, Dravet syndrome, Rasmussen’s encephalitis,
absence epilepsy, and acute ‘symptomatic’ seizures. There
is, unfortunately, no agreement as to the mechanism(s) of
corticosteroid actions as an anticonvulsant. However, a
study by Di Chiara et al. [31] found in a rat model that
glucocorticoids may simultaneously influence different
pathways that differentially facilitate inhibitory GABA
release and inhibit excitatory glutamate release, thus
summing to an overall effect of neuronal suppression.
Relevancy to epilepsy, LKS and R-ASD is merely specula-
tive at this point. As reviewed by Chatham and Kimberly
[39], corticosteroids manifest a well-documented multipli-
city of cellular effects that may be relevant to treatment of
immune disorders such as lupus. Again, the relevancy to
R-ASD remains to be established.
Hopefully a better understanding of corticosteroid action
mechanisms may lead to the development a more precisely
targeted drug that has fewer secondary complications and
is useful in epilepsy treatment as well as the amelioration
of R-ASD symptomatology.
The current study benefits from the availability of the
simple and objective FMAER test that is relevant not onlyfor detection of response amplitude changes but also of
response distortion. Nevertheless the current study has
very significant limitations that preclude conclusions as to
the effectiveness of steroid treatment for regressive autism.
The study, however, appears to provide sufficient indica-
tion in support of the need for a prospective, randomized,
double blind, placebo controlled, cross-over design trial
in order to assess more rigorously the potential role of
steroids in R-ASD.
Study limitations as indicated above include but are
not limited to the following:
(1) The study was retrospective.
(2) The STAR and NSA groups were similar yet did
not meet all of the same selection criteria. The
STAR group was composed exclusively of children
with regressive autism while the NSA group was
composed mostly of children with autism without
history of regression.
(3) Aside from the FMAER different language
measures were applied to STAR and NSA group.
Neither of the language measures is standardized
or published.
(4) Quantification of the DSM-IV symptom list as a
measure of behavior is also unpublished and not in
standard usage; moreover this measure was only
available for the STAR group.
(5) Analysis by ANOVA with interaction and possibly
with covariates would be preferred over paired
T-test if the groups were more comparable initially.
(6) Aside from the FMAER the language and behavior
data were obtained by clinicians in collaboration with
the parents rather than by independent observers.
(7) The one year follow-up is inadequate in terms of
length of time from treatment and in terms of the
rigor of the language and behavior data gathered.Conclusion
Children with R-ASD, and without concurrent evi-
dence for an epileptic encephalopathy such as the
Landau-Kleffner syndrome, who receive steroid ther-
apy, show improvement in a language specific elec-
trophysiological brain function indicator, as measured
with the FMAER. Additionally, they appear to show
improvement in language and behavior performance.
At the level utilized in this study, steroid therapy
did not appear to result in recognized, lasting
morbidities.
The current study augments prior demonstrations
of the utility of the FMAER as a quantified and ob-
jective tool for the study of childhood language disor-
ders [16]; the FMAER appears sensitive not just to
the presence or absence of a response and to response
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prominent in R-ASD. Although the current study goes be-
yond single case reports in suggesting a positive steroid
response in regressive autism, it mainly serves to support
the need for a more formal, prospective study as noted
above.
The current study does not suggest that steroids ‘cure’
regressive autism nor does it claim proof of the value of
pharmacological treatment of regressive autism.
The following questions are left unanswered and require
future investigations:
(1) Will a formal prospective randomized, double
blind, placebo controlled, crossover study validate
current results?
(2) Will results differ if steroids were delivered sooner
after regression rather than several months later as
was the case for the current study?
(3) How will steroid therapy compare to
anticonvulsant therapy or other medication trials in
ameliorating R-ASD?
(4) Will the beneficial effects of steroids endure
beyond a year?
(5) What will be the implications of a positive steroid
response to the hypothesis of an inflammatory
nature of regression in ASD?
(6) Will early MEG and/or dense EEG array studies of
R-ASD patients demonstrate epileptiform discharges
not observed by EEG?
(7) Will steroids play a role in the treatment of
non-regressive autism?
(8) Will distortion of the FMAER be demonstrable in
forms of central auditory processing syndromes
other than regressive autism?
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